Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma
ConclusionsMore than half and more than one-third of patients with renal cell carcinoma receiving VEGFR-TKIs experienced any and severe anti-angiogenesis-related adverse events, respectively. The relative dose intensity of VEGFR-TKI treatment was associated with anti-angiogenesis-related adverse events.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Bleeding | Cancer & Oncology | Carcinoma | Hypertension | Hypothyroidism | Kidney Cancer | Oral Cancer | Proteinuria | Renal Cell Carcinoma | South Korea Health | Study | Thrombosis